{"title":"SGLT2抑制剂治疗无糖尿病低左室射血分数心衰患者的疗效和安全性综述","authors":"E. V. Lomakin","doi":"10.33920/med-03-2209-08","DOIUrl":null,"url":null,"abstract":"Heart failure (HF) with low left ventricular ejection fraction (LVEF) is a disease with an unfavorable prognosis, for the treatment of which there is a need to search for drugs that improve patients’ quality of life. Such a group of drugs is inhibitors of sodium-glucose cotransporter type 2 (iSGLT-2). Purpose of the study: to assess the efficacy and safety of the new class of antihyperglycemic drugs — iSGLT-2.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"27 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Review of the efficacy and safety of SGLT2 inhibitors in heart failure patients with low left ventricular ejection fraction without diabetes mellitus\",\"authors\":\"E. V. Lomakin\",\"doi\":\"10.33920/med-03-2209-08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Heart failure (HF) with low left ventricular ejection fraction (LVEF) is a disease with an unfavorable prognosis, for the treatment of which there is a need to search for drugs that improve patients’ quality of life. Such a group of drugs is inhibitors of sodium-glucose cotransporter type 2 (iSGLT-2). Purpose of the study: to assess the efficacy and safety of the new class of antihyperglycemic drugs — iSGLT-2.\",\"PeriodicalId\":406478,\"journal\":{\"name\":\"Glavvrač (Chief Medical Officer)\",\"volume\":\"27 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Glavvrač (Chief Medical Officer)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33920/med-03-2209-08\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Glavvrač (Chief Medical Officer)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33920/med-03-2209-08","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Review of the efficacy and safety of SGLT2 inhibitors in heart failure patients with low left ventricular ejection fraction without diabetes mellitus
Heart failure (HF) with low left ventricular ejection fraction (LVEF) is a disease with an unfavorable prognosis, for the treatment of which there is a need to search for drugs that improve patients’ quality of life. Such a group of drugs is inhibitors of sodium-glucose cotransporter type 2 (iSGLT-2). Purpose of the study: to assess the efficacy and safety of the new class of antihyperglycemic drugs — iSGLT-2.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
